PA8750901A1 - Bifenilsulfonilos y fenil heteroaril sulfonilos como moduladores del receptor h3 de histamina utiles para el tratamiento de los trastornos relacionados con dicho receptor - Google Patents
Bifenilsulfonilos y fenil heteroaril sulfonilos como moduladores del receptor h3 de histamina utiles para el tratamiento de los trastornos relacionados con dicho receptorInfo
- Publication number
- PA8750901A1 PA8750901A1 PA20078750901A PA8750901A PA8750901A1 PA 8750901 A1 PA8750901 A1 PA 8750901A1 PA 20078750901 A PA20078750901 A PA 20078750901A PA 8750901 A PA8750901 A PA 8750901A PA 8750901 A1 PA8750901 A1 PA 8750901A1
- Authority
- PA
- Panama
- Prior art keywords
- disorders
- treatment
- histamine
- receptor
- symposia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
LA PRESENTE INVENCION SE RELACIONA CON CIERTOS DERIVADOS DE BIFENIL SULFONAMIDA DE FORMULA (LA) Y COMPOSICIONES FARMACEUTICAS DE ESTOS QUE MODULAN LA ACTIVIDAD DEL RECEPTOR H3 DE HISTAMINA. LOS COMPUESTOS DE LA PRESENTE INVENCION Y SUS COMPOSICIONES FARMACEUTICAS ESTAN DIRIGIDOS A METODOS UTILES EN EL TRATAMIENTO DE TRASTORNOS ASOCIADOS AL RECEPTOR H3 DE HISTAMINA, COMO TRASTORNOS COGNOSCITIVOS, EPILEPSIA, LESIO CEREBRAL, DEPRESION. OBESIDAD, TRASTORNO DEL SUEÑO Y LA VIGILIA COMO NARCOLEPSIA, TRASTORNOS DEL SUEÑO POR CAMBIO DE TURNO DE TRABAJO, SOMNOLENCIA COMO EFECTO COLATERAL DE UN MEDICAMENTO, MANTENIMIENTO DEL ESTADO DE ALERTA PARA AYUDAR A COMPLETAR TAREAS Y SIMILARES, CATAPLEJIA, HIPERSOMNIA, SINDROME DE SOMNOLENCIA, SINDROME DE CAMBIO RAPIDO DE HUSOS HORAIOS O JET LAG, APNEA DEL SUEÑO Y SIMILARES, TRASTORNOS DE HIPERACTIVIDAD POR DEFICIT ATENCIONAL (THDA), ESQUIZOFRENIA, ALERGIAS, RESPUESTAS ALERGICAS EN LAS VIAS RESPIRATORIAS SUPERIORES, RINITIS ALERGICA, CONGESTION NASAL, DEMENCIA, ENFERMEDAD DE ALZHIMER Y SIMILARES.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85261006P | 2006-10-17 | 2006-10-17 | |
US93435807P | 2007-06-11 | 2007-06-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8750901A1 true PA8750901A1 (es) | 2009-03-31 |
Family
ID=39149258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20078750901A PA8750901A1 (es) | 2006-10-17 | 2007-10-17 | Bifenilsulfonilos y fenil heteroaril sulfonilos como moduladores del receptor h3 de histamina utiles para el tratamiento de los trastornos relacionados con dicho receptor |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100240653A1 (es) |
EP (1) | EP2074086B1 (es) |
JP (1) | JP2010506918A (es) |
KR (1) | KR20090069333A (es) |
AR (1) | AR063226A1 (es) |
AT (1) | ATE512948T1 (es) |
AU (1) | AU2007313180A1 (es) |
CA (1) | CA2665204A1 (es) |
CL (1) | CL2007002977A1 (es) |
EA (1) | EA200970386A1 (es) |
IL (1) | IL197892A0 (es) |
MX (1) | MX2009004071A (es) |
PA (1) | PA8750901A1 (es) |
PE (1) | PE20081462A1 (es) |
TW (1) | TW200823204A (es) |
WO (1) | WO2008048609A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004000260T2 (de) | 2003-07-22 | 2006-08-24 | Arena Pharmaceuticals, Inc., San Diego | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物 |
JP2010529130A (ja) * | 2007-06-08 | 2010-08-26 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (r)−1−{2−[4’−(3−メトキシ−プロパン−1−スルホニル)−ビフェニル−4−イル]−エチル}−2−メチル−ピロリジンの結晶形、およびその組成物ならびにそれに関連する方法 |
WO2009023253A2 (en) | 2007-08-15 | 2009-02-19 | Arena Pharmaceuticals Inc. | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
US20110021538A1 (en) * | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
WO2009128907A1 (en) * | 2008-04-16 | 2009-10-22 | Arena Pharmaceuticals, Inc. | Processes useful for the synthesis of (r)-1-{2-[4'-(3-methoxypropane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine |
ES2666324T3 (es) * | 2008-10-28 | 2018-05-04 | Arena Pharmaceuticals, Inc. | Composiciones de un modulador del receptor de serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con el mismo |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
GB201005511D0 (en) | 2010-03-31 | 2010-05-19 | Takeda Pharmaceutical | Compounds and their use |
FR2974729B1 (fr) * | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
DK3309150T3 (da) * | 2013-01-09 | 2021-08-30 | Arena Pharm Inc | (r)-3-(4'-(2-(2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-yl)propansyre som histamin-h3-receptormodulatorer til behandlingen af kognitive lidelser |
JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
RU2018103338A (ru) | 2015-07-15 | 2019-08-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием |
WO2020092604A1 (en) * | 2018-10-30 | 2020-05-07 | Concert Pharmaceuticals, Inc. | Deuterated pitolisant |
WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
CN115160584B (zh) * | 2022-07-06 | 2024-03-22 | 西北工业大学 | 一种基于阳离子-π与静电作用协同构筑异质孔超分子有机框架及制备方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5352707A (en) * | 1992-03-26 | 1994-10-04 | Harbor Branch Oceanographic Institution, Inc. | Method for treating airway congestion |
US5217986A (en) * | 1992-03-26 | 1993-06-08 | Harbor Branch Oceanographic Institution, Inc. | Anti-allergy agent |
ATE167861T1 (de) * | 1992-09-14 | 1998-07-15 | Takeda Chemical Industries Ltd | 1,2,4-oxadiazolyl oder 1,2,4-thiadiazolyl- derivate als angiotensin ii antagonisten |
US5541217A (en) * | 1995-05-17 | 1996-07-30 | Ortho Pharmaceutical Corporation | 4-arylcyclopenta[c]pyrrole analgesics |
US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
DE19937537A1 (de) * | 1999-08-09 | 2001-03-08 | Gruenenthal Gmbh | Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate |
US20040044029A1 (en) * | 2002-08-14 | 2004-03-04 | Dart Michael J. | Azabicyclic compounds are central nervous system active agents |
US7244852B2 (en) * | 2003-02-27 | 2007-07-17 | Abbott Laboratories | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof |
GB0308333D0 (en) * | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
US7632857B2 (en) * | 2004-04-01 | 2009-12-15 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
US20050245543A1 (en) * | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
US7145005B2 (en) * | 2004-05-12 | 2006-12-05 | Abbott Laboratories | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation |
DE602005014124D1 (de) * | 2004-09-07 | 2009-06-04 | Banyu Pharma Co Ltd | Carbamoylsubstituiertes spiro-derivat |
AU2005311534B2 (en) * | 2004-12-03 | 2011-02-17 | F. Hoffmann-La Roche Ag | 3-substituted pyridine derivatives as H3 antagonists |
BRPI0606502A2 (pt) * | 2005-01-19 | 2009-06-30 | Hoffmann La Roche | compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento ou prevenção de doenças que são associadas com a modulação de receptores h3; método para o tratamento ou prevenção de obesidade em um ser humano ou animal; método de tratamento ou prevenção de diabetes tipo ii em um ser humano ou animal e usos de compostos |
US20060188960A1 (en) * | 2005-02-18 | 2006-08-24 | Waters Stephen M | Chimeric histamine H3 receptor |
DK1899334T3 (da) * | 2005-06-17 | 2008-11-24 | Janssen Pharmaceutica Nv | Naphthyridinforbindelser |
DK1948607T3 (da) * | 2005-09-16 | 2010-07-26 | Janssen Pharmaceutica Nv | Cyclopropylaminer med histamin-H3-receptormodulatorer |
JP4879997B2 (ja) * | 2005-11-30 | 2012-02-22 | エフ.ホフマン−ラ ロシュ アーゲー | 1,5−置換インドール−2−イルアミド誘導体 |
PE20071136A1 (es) * | 2005-12-21 | 2007-12-29 | Schering Corp | Derivados de anilina sustituida como antagonistas de la histamina h3 |
BRPI0709612A2 (pt) * | 2006-03-15 | 2011-07-19 | Wyeth Corp | composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i |
CN101432261A (zh) * | 2006-05-19 | 2009-05-13 | 惠氏公司 | 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺 |
WO2007143422A2 (en) * | 2006-05-30 | 2007-12-13 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
WO2008005338A1 (en) * | 2006-06-29 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
US7648979B2 (en) * | 2007-02-07 | 2010-01-19 | Hoffmann-La Roche Inc. | 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives |
US7557108B2 (en) * | 2007-02-07 | 2009-07-07 | Hoffmann-La Roche Inc. | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones |
US7507736B2 (en) * | 2007-02-07 | 2009-03-24 | Hoffmann-La Roche Inc. | Indol-2-yl-piperazin-1-yl-methanone derivatives |
US7846930B2 (en) * | 2007-05-18 | 2010-12-07 | Janssen Pharmaceutica Nv | Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators |
WO2008147945A1 (en) * | 2007-05-24 | 2008-12-04 | Wyeth | Azacyclylbenzamide derivatives as histamine-3 antagonists |
EA201000316A1 (ru) * | 2007-09-12 | 2010-10-29 | ВАЙЕТ ЭлЭлСи | Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа |
TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
WO2009067406A1 (en) * | 2007-11-20 | 2009-05-28 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
US8236792B2 (en) * | 2008-05-23 | 2012-08-07 | Janssen Pharmaceutica Nv | Substituted pyrrolidine amides as modulators of the histamine H3 receptor |
US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
-
2007
- 2007-09-28 TW TW096136478A patent/TW200823204A/zh unknown
- 2007-10-10 AR ARP070104474A patent/AR063226A1/es not_active Application Discontinuation
- 2007-10-16 MX MX2009004071A patent/MX2009004071A/es active IP Right Grant
- 2007-10-16 KR KR1020097009992A patent/KR20090069333A/ko not_active Application Discontinuation
- 2007-10-16 EP EP07852791A patent/EP2074086B1/en active Active
- 2007-10-16 EA EA200970386A patent/EA200970386A1/ru unknown
- 2007-10-16 US US12/445,795 patent/US20100240653A1/en not_active Abandoned
- 2007-10-16 AU AU2007313180A patent/AU2007313180A1/en not_active Abandoned
- 2007-10-16 WO PCT/US2007/022086 patent/WO2008048609A1/en active Application Filing
- 2007-10-16 JP JP2009533349A patent/JP2010506918A/ja not_active Withdrawn
- 2007-10-16 PE PE2007001398A patent/PE20081462A1/es not_active Application Discontinuation
- 2007-10-16 AT AT07852791T patent/ATE512948T1/de not_active IP Right Cessation
- 2007-10-16 CA CA002665204A patent/CA2665204A1/en not_active Abandoned
- 2007-10-17 CL CL200702977A patent/CL2007002977A1/es unknown
- 2007-10-17 PA PA20078750901A patent/PA8750901A1/es unknown
-
2009
- 2009-04-05 IL IL197892A patent/IL197892A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
ATE512948T1 (de) | 2011-07-15 |
EP2074086A1 (en) | 2009-07-01 |
CA2665204A1 (en) | 2008-04-24 |
IL197892A0 (en) | 2009-12-24 |
PE20081462A1 (es) | 2008-10-18 |
KR20090069333A (ko) | 2009-06-30 |
AU2007313180A1 (en) | 2008-04-24 |
MX2009004071A (es) | 2009-04-28 |
EA200970386A1 (ru) | 2009-10-30 |
EP2074086B1 (en) | 2011-06-15 |
US20100240653A1 (en) | 2010-09-23 |
CL2007002977A1 (es) | 2008-06-06 |
AR063226A1 (es) | 2009-01-14 |
TW200823204A (en) | 2008-06-01 |
JP2010506918A (ja) | 2010-03-04 |
WO2008048609A1 (en) | 2008-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8750901A1 (es) | Bifenilsulfonilos y fenil heteroaril sulfonilos como moduladores del receptor h3 de histamina utiles para el tratamiento de los trastornos relacionados con dicho receptor | |
UY29882A1 (es) | Antagonistas del receptor 3 de la histamina | |
NI200600306A (es) | Derivados de sulfamida y sulfamato para el tratamiento de la epilepsia y trastornos relacionados | |
CU20180056A7 (es) | Derivados de 2-fenil-3-(piperazinometil)imidazo(1,2-a)piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios | |
CR20130308A (es) | Compuestos y su uso como inhibidores de bace | |
CU24036B1 (es) | Derivados de benzofuranilo | |
BR112014029868A2 (pt) | compostos, e, composição farmacêutica | |
DOP2019000171A (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
BRPI0721088B8 (pt) | processo para a preparação de derivados de piperazinil e diazepanil benzamida | |
CR10062A (es) | Composiciones y metodos de tratamiento para trastornos del sistema nervioso central | |
CL2013001073A1 (es) | Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras. | |
BRPI0820668A2 (pt) | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina | |
ECSP19044577A (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
GT201400109A (es) | Derivados de 6,7-dihidro-5h-benzo(7)anuleno, procesos para su preparación, productos farmacéuticos que comprenden a los mismos y su uso en la preparacion de medicamentos. | |
CO6491096A2 (es) | Derivados de cromona, procesos para su preparación y aplicaciones terapeúticas de los mismos | |
CO6481008A2 (es) | Canfenos arilados novedosos, procesos para su preparación y usos | |
UY30262A1 (es) | Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada | |
CO6331428A2 (es) | Compuestos que comprenden un grupo ciclobutoxi | |
AR065431A1 (es) | Formas solidas que comprenden (-) -o-desmetilvenlafaxina y usos de las mismas. | |
CL2011000184A1 (es) | Compuestos derivados de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno; agonista de receptores de melatonina; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a los compuestos; y su uso de los compuestos en la preparacion de medicamentos. | |
DOP2021000105A (es) | Proceso para la producción de formas farmacéuticas que contienen inhibidores de los canales task1 y task3 y su uso para la terapia de trastornos respiratorios | |
UY30529A1 (es) | Compuestos de 1h-quinolin-4-ona, procedimientos, usos y composiciones | |
BR112016001545A2 (pt) | Derivados de pirroloquinolina como antagonistas 5-ht6, método de preparação e uso dos mesmos | |
WO2007061741A3 (en) | Modulators of the h3 receptor useful for the treatment of disorders related thereto | |
UY30217A1 (es) | 1-amino-4-fenildihidroisoquinolinas sustituidas, procedimiento para su preparacion, su uso como medicamento, y medicamento que las comprende. |